The pharmaceutical sector is expected to thrive due to the rising demand for advanced medicines to treat lifestyle diseases and its increasing ability to meet quality treatment needs thanks to technological...
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Amneal Pharmaceuticals, Inc. ("Amneal" or the "Company") (NYSE: AMRX). Such...
Stocks that traded heavily or had substantial price changes on Wednesday: MP Materials, Wolfspeed rise; Amneal, Knight-Swift fall
The company received a complete response letter from the FDA regarding a Parkinson's disease generic therapy.
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) announced its actual results today for the first quarter ended March 31, 2023.
Theravance Bio (TBPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Amneal (AMRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.